Radnor Capital Management LLC Sells 245 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Radnor Capital Management LLC trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,980 shares of the specialty pharmaceutical company’s stock after selling 245 shares during the quarter. Radnor Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $889,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Swedbank AB acquired a new position in shares of Jazz Pharmaceuticals in the second quarter valued at about $106,936,000. Vanguard Group Inc. grew its position in shares of Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares in the last quarter. LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 1.6% in the first quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock valued at $286,703,000 after buying an additional 37,631 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Jazz Pharmaceuticals by 25.5% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 33,219 shares of the specialty pharmaceutical company’s stock valued at $4,000,000 after buying an additional 6,756 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp boosted its stake in shares of Jazz Pharmaceuticals by 131.9% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 73,757 shares of the specialty pharmaceutical company’s stock valued at $8,818,000 after buying an additional 41,950 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on JAZZ shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Royal Bank of Canada boosted their price target on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, October 23rd. Piper Sandler reduced their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Finally, Morgan Stanley reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $173.43.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Up 0.1 %

Shares of JAZZ opened at $111.55 on Thursday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.48. The stock has a market capitalization of $6.89 billion, a price-to-earnings ratio of 19.17, a PEG ratio of 1.37 and a beta of 0.57. The stock has a fifty day moving average of $110.42 and a 200-day moving average of $109.61.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.